idarubicinol has been researched along with docetaxel anhydrous in 1 studies
Studies (idarubicinol) | Trials (idarubicinol) | Recent Studies (post-2010) (idarubicinol) | Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) |
---|---|---|---|---|---|
54 | 10 | 0 | 12,110 | 3,216 | 6,920 |
Protein | Taxonomy | idarubicinol (IC50) | docetaxel anhydrous (IC50) |
---|---|---|---|
Kinesin-like protein KIF11 | Homo sapiens (human) | 0.0014 | |
Nucleotide-binding oligomerization domain-containing protein 2 | Homo sapiens (human) | 5.0119 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Aita, P; Bearz, A; Boiocchi, M; Colussi, AM; Corona, G; Crivellari, D; Robieux, I; Sorio, R; Stocco, F; Toffoli, G | 1 |
1 trial(s) available for idarubicinol and docetaxel anhydrous
Article | Year |
---|---|
Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Cyclophosphamide; Daunorubicin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Idarubicin; Maximum Tolerated Dose; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors | 2000 |